Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Mexicano Del Seguro SocialfiledCriticalInst Mexicano Del Seguro Social
Priority to MX2016007881ApriorityCriticalpatent/MX2016007881A/en
Publication of MX2016007881ApublicationCriticalpatent/MX2016007881A/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
The present disclosure is related to the use of an Ageratina pichinchensis organic extract standardized in the content of its active compound 7-O-(ß-D-Glucopyranosyl)-galectin, for the preparation of a pharmaceutical composition useful in the treatment of the minor recurrent aphthous stomatitis. The present invention is based on the evaluation of the clinical and therapeutic efficacy and safety of a pharmaceutical formulation made with a decolorized hexane-ethyl acetate extract of Ageratina pichinchensis with a concentration of 5% in patients with a clinical picture of the minor recurrent aphthous stomatitis.
MX2016007881A2016-06-162016-06-16Use of an ageratina pichinchensis extract for the treatment of the minor recurrent aphthous stomatitis.
MX2016007881A
(en)
Derivative of n2, n4-diphenylpyrimidine-2,4-diamine, method for the preparation thereof, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of cancer.
pharmaceutical combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases, pharmaceutical composition, their uses, and kit
medicament, use of brexpiprazole or a pharmaceutically acceptable salt thereof, methods for preventing or treating a substance related disorder and for producing a pharmaceutical composition, pharmaceutical composition, and kit.